Journal
NATURE MEDICINE
Volume 15, Issue 3, Pages 338-344Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.1930
Keywords
-
Funding
- US National Institutes of Health [CA95152, CA059350, CA08748, CA086438, CA096945, CA094060, CA083084]
- Alliance for Cancer Gene Therapy
- Damon Runyon Clinical Investigator Award
- Canada Club of New York, Kate's Team
- Commonwealth Cancer Foundation for Research and the Experimental Therapeutics Center of MSKCC
- Geoffrey Beene Cancer Foundation
- Chronic Lymphocytic Leukemia Foundation
- Ludwig Center for Cancer Immunotherapy
- Bocina Cancer Research Fund
Ask authors/readers for more resources
We developed a new approach to bioluminescent T cell imaging using a membrane-anchored form of the Gaussia luciferase (GLuc) enzyme, termed extGLuc, which we could stably express in both mouse and human primary T cells. In vitro, extGLuc(+) cells emitted significantly higher bioluminescent signal when compared to cells expressing GLuc, Renilla luciferase (RLuc) or membrane-anchored RLuc (extRLuc). In vivo, mouse extGLuc(+) T cells showed higher bioluminescent signal when compared to GLuc(+) and RLuc(+) T cells. Application of this imaging approach to human T cells genetically modified to express tumor-specific chimeric antigen receptors (CARs) enabled us to show in vivo CAR-mediated T cell accumulation in tumor, T cell persistence over time and concomitant imaging of T cells and tumor cells modified to express firefly luciferase. This sensitive imaging technology has application to many in vivo cell-based studies in a wide array of mouse models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available